Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?

INR, international normalised ratio; LSM, liver stiffness measurement; Plt, platelet count. 7 Miró Òscar, Llorens P, Jiménez S, et al. A casecontrol emergency departmentbased analysis of acute pancreatitis in Covid19: results of the UMC19S6. J Hepatobiliary Pancreat Sci 2020. doi:10.1002/ jhbp.873. [Epub ahead of print: 01 Dec 2020]. 8 Szatmary P, Arora A, Thomas Raraty MG, et al. Emerging phenotype of severe acute respiratory syndromecoronavirus 2associated pancreatitis. Gastroenterology 2020;159:1551–4. 9 Vatansev H, Yıldırım MA, Kuccukturk S, et al. Clinical evaluation of acute pancreatitis caused by SARSCoV2 virus infection. Gastroenterol Res Pract 2021;2021:1–5. 10 Ding P, Song B, Liu X, et al. Elevated pancreatic enzymes in ICU patients with COVID19 in Wuhan, China: a retrospective study. Front Med 2021;8:663646. 11 Karaali R, Topal F. Evaluating the effect of SARSCov2 infection on prognosis and mortality in patients with acute pancreatitis. Am J Emerg Med 2021;49:378–84.

[1]  M. Ronot,et al.  Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD , 2021, European Radiology.

[2]  E. Tsochatzis,et al.  Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? , 2021, Gut.

[3]  V. Wong,et al.  Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis , 2021, Gut.

[4]  V. Wong,et al.  Liver stiffness measurement predicts long‐term survival and complications in non‐alcoholic fatty liver disease , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[5]  S. Asch,et al.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[6]  V. Wong,et al.  Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. , 2018, Journal of hepatology.

[7]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[8]  R. Franchis.  Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension , 2015 .

[9]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[10]  R. de Franchis.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. , 2015, Journal of hepatology.